Meeting
2019 ASCO Annual Meeting
Genomic characterization of lung tumors and metastatic (Met) sites in advanced (Adv) NSCLC.
Authors
Melinda D Willard
Eli Lilly and Company, Indianapolis, IN
Melinda D Willard , Emily Nash Nash Smyth , Ramon Velasquez Tiu , Julie Beyrer , Yajun Emily Zhu , Lee Bowman , Kristin M Sheffield , Yimei Han , Priscilla Brastianos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2014)
DOI
10.1200/JCO.2019.37.15_suppl.2014
Abstract #
2014
Poster Bd #
203
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer.
First Author: Aurélie Swalduz
Poster
2023 ASCO Annual Meeting
Effects of mutations in SWI/SNF subunits on context-specific prognosis in driver positive and driver negative NSCLC.
First Author: Benjamin Herzberg
Poster
2021 ASCO Annual Meeting
Genomic landscape differences in patients with advanced non-small cell lung cancer by sex and age.
First Author: ErinMarie Kimbrough
Poster
2020 ASCO Virtual Scientific Program
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
First Author: Jia Luo